Prof. Mohammad Obeid is recognized among the top 2% researchers in the world as announced by Stanford University, 2025.This ranking reflects the collective effort of his collaborators, mentors, and the entire research community that he is proud to be a part of.
Dr. Saif Aldeen Jaber has received notable recognition from WILEY for his research, with one of his articles being listed among the top viewed publications in the journal Polymer Engineering & Science. The highlighted work, titled "The effect of polymeric films of hydroxypropyl methylcellulose (HPMC)/chitosan on ofloxacin release, diffusion, and biological activity," explores the formulation and performance of HPMC/chitosan-based polymeric films, emphasizing their impact on the controlled release and bioactivity of the antibiotic ofloxacin. This achievement underscores Dr. Jaber’s significant contributions to the field of pharmaceutical polymers and drug delivery systems.
Dr. Zahra Rattray, a key member of the IOPDDT group, has earned international recognition for her research, leadership, and teaching. In 2024, she was appointed Member of the University Court, received the University of Strathclyde Medal and Strathclyde Teaching Excellence Award, and was elected Fellow of the Royal Pharmaceutical Society (FRPS) and Fellow of the Royal Society of Edinburgh Young Academy of Scotland (RSE‑YAS). In 2023, she was honored by the Women in Leadership Network+, awarded the Sir Robin MacLellan Award, included in the Saltire Society’s 40 Under 40 List, and received the Academy of Pharmaceutical Sciences Emerging Scientist Award. In 2022, she was elected Fellow of the Academy of Pharmaceutical Sciences of Great Britain and received the FIPWise Rising Star Award, and in 2021, she participated in the European Crucible: Scottish Cohort and received the European Crucible Seed Funding Award. These accolades underscore her sustained impact, innovation, and leadership in pharmaceutics. For more details: https://pureportal.strath.ac.uk/en/persons/zahra-rattray/prizes
We are pleased to announce that Prof. Ala’ al-Jabali and Prof. Mohammad Obeid have co-authored the paper titled “Small non-coding RNAs as therapeutic targets with delivery strategies in cancer treatment and their clinical applications”, published in the International Journal of Pharmaceutics.
Read more about Small non-coding RNAs as therapeutic targets in their recently published article.
https://doi.org/10.1016/j.ijpharm.2025.126231
Dr. Zahra Rattray is a co-inventor on multiple patents in advanced protein- and antibody-based therapeutics. These include “Binding Proteins 2” (EU WO/2019/018428, issued 2019), “Compositions and Methods for Enhancing Nuclear Translocation” (US WO2019152806, filed 2019), and “Compositions and Methods for Inhibition of Nuclear-Penetrating Antibodies” (US WO2019152808, filed 2019). Together, these patents demonstrate her innovative work in designing targeted molecular strategies and next-generation biologics for therapeutic applications.